Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

cinepazide

Known as: 1-((1-pyrrolidinylcarbonyl)methyl)-4-(3,4,5-trimethoxycinnamoyl)piperazine 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Background and ObjectiveMildronate, an inhibitor of carnitine-dependent metabolism, is considered to be an anti-ischemic drug… Expand
  • figure 1
  • table 1
  • table 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND Since the publication of a major international case-control study on the risk of agranulocytosis associated with the… Expand
  • figure I
  • table 1
  • table 2
Is this relevant?
1991
1991
The risks of agranulocytosis and aplastic anemia in relation to the use of cardiovascular drugs were estimated in a population… Expand
Is this relevant?
1988
1988
We studied the effects of a series of 16 vasodilators on the intrahepatic vasoconstriction induced by norepinephrine in the… Expand
Is this relevant?
1984
1984
The effects of cinepazide, 1-[(1-pyrrolidinylcarbonyl)methyl]-4-(3,4,5-trimethoxycinnamoyl )piperazine hydrogen maleate, were… Expand
Is this relevant?
1980
1980
Physical dependence liability to cinepazide was studied, and the following were found : 1. Rats were applied cinepazide for 96… Expand
Is this relevant?
1980
1980
The negative inotropic effects of adenosine and adenine nucleotides, such as ATP and cAMP, on guinea-pig atria were selectively… Expand
Is this relevant?
1979
1979
Cardiovascular effects of cinepazide were compared with those of cinnarizine and papaverine. Cinepazide (3-30 mg/kg, i.v… Expand
Is this relevant?
1979
1979
Effects of cinepazide, a vasoactive agent, on regional circulations in various sites of brain and other organs in curarized… Expand
Is this relevant?
1976
1976
1. An oral dose of the coronary vasodilator 4-(3,4,5-trimethoxy[14C]cinnamoyl)-1-(N-pyrrolidinocarbonylmethyl)piperazine was well… Expand
Is this relevant?